Associated Papers
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer.
Berg T et al.
Neoplasia (new York, N.y.), 2025
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing.
Kostecka A et al.
Npj Breast Cancer, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
TP53 mutations and CDKN2A mutations/deletions are highly recurrent molecular alterations in the malignant progression of sinonasal papillomas.
Brown NA et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2021
Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
Lapke N et al.
Bmc Cancer, 2021
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Takayanagi D et al.
Cancers, 2021
Cancer-related gene mutations and intratumoral genetic heterogeneity in human epidermal growth factor receptor 2 heterogeneous gastric cancer.
Kanayama K et al.
Pathology International, 2020
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers.
Lee KH et al.
Cancers, 2019
Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study.
Lupini L et al.
European Journal of Cancer Care, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.
Wang Y et al.
Frontiers in Oncology, 2019
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L et al.
Nature Communications, 2018
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Ross RL et al.
Bmc Cancer, 2016
Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
Burghel GJ et al.
Biomed Research International, 2015
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G et al.
Plos One, 2015
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA et al.
Hematology/oncology and Stem Cell Therapy, 2014
PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
Ross RL et al.
Oncogene, 2013
PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
Dong Y et al.
Human Pathology, 2012
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.
Cizkova M et al.
Breast Cancer Research : Bcr, 2012
[Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2011
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.
Rudd ML et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.
Knowles MA et al.
Cancer Metastasis Reviews, 2009
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.
Platt FM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Hayes MP et al.
Gynecologic Oncology, 2009